Evaluation of Heparin & Enoxaparin regimen internal patient at sina hospital in Tabriz, September 97-96

Abstract

Introduction: Deep vein thrombosis is a serious threat to clinical patients, while Deep Venus Thrombosis (DVT) can be prevented. DVT causes 10% of deaths in the hospital population. DVT prevention methods include the use of medicines such as heparin and enoxaparin and mechanical measures such as varicose socks. Objective: A review of the logistic prophylaxis of DVT was conducted in the clinical patients of Sina hospital. Materials and methods: This is a case study which was conducted on clinical patients in different parts of Sina hospital in Tabriz in 1397. Samples were screened using a questionnaire including demographic characteristics (age, weight, height, ...), history of underlying diseases, diagnosis of current disease, type of prophylaxis, tests, received medicines, checklist for risk assessment of patients with thrombosis based on GENEVA Score (0-2: low risk, equal to or greater than 3: high risk), as well as a risk assessment check list for the bleeding factor (0-7: safe and more or equal to 7: high risk). Results: The mean age of the patients was 59.56 and the majority of them were men. 70.18% of the patients got DVT indication, 86.38% of them got heparin, and 14.44% got enoxaparin and 1.79% of varicose socks. 14.3% of patients had a bleeding risk factor. 85.29% of patients did not need anticoagulant, but 91% got heparin and 9% enoxaparin. Discussion: The total cost of the anti-coagulant was 454420000 Rials, which 68270500 Rials were unreasonable (Heparin Loss Cost: 54406500 Rials, Enoxaparin: 13114000 Rials, and Varicose Socks: 750000 Rials).